CLAIM CARD
Quantitative findings from this clinical RCT were uniformly null across the key frailty-related endpoints. These p-values, detailed in Table 2, indicate no robust evidence of benefit. The consistent lack of statistical significance across multiple endpoints suggests that, within this trial's parameters, aspirin did not meaningfully alter the trajectory from prefrail or frail to a more robust state.
Evidence grade: exploratory
Contradiction status: none
Publication: 4ff5f065-8b09-4580-9cbc-da14dbcaa1fa
Provenance: Derivation Web chain
Citation Support
source_1Flensted-Jensen 2025source_2Saeed 2026source_3Zhu 2026source_4Navarese 2026source_5Yan 2024